Clinical Trials on Open Angle Glaucoma and Cataract in Japan

Total 29 results

Santen Pharmaceutical Co., Ltd.

Completed

To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
Alcon Research

Completed

Safety and Efficacy of Travoprost/Timolol BAC-free

Ocular Hypertension | Open-Angle Glaucoma

Japan
Alcon, a Novartis Company

Completed

Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

Ocular Hypertension | Open-Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

Primary Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Recruiting

A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma, Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma, Ocular Hypertension

Japan
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
AbbVie

Recruiting

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States, Japan
Bausch & Lomb Incorporated

Completed

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

Ocular Hypertension | Glaucoma

Japan
Bayer

Recruiting

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Neovascular Glaucoma

Japan
Alcon Research

Completed

Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

Ocular Hypertension | Normal Tension Glaucoma

Japan
University of Occupational and Environmental Health

Unknown

Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome (Effect of CTR)

Cataract With Exfoliation Syndrome

Japan
Showa University

Completed

The Effect of a Blue Light Filtering IOL

to Compare the Effect of Two Types of IOLs | on the Incidence of Cystoid Macular Edema | After Cataract Surgery

Japan
Alcon Research

Completed

Alcon® Ex-PRESS® Glaucoma Filtration Device in Japanese Patients

Glaucoma

Japan
Kyorin University

Completed

Macular Retinoschisis and Detachment Associated With Glaucomatous Optic Neuropathy

Normal Tension Glaucoma | Macular Retinoschisis | Macular Detachment

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

Ocular Hypertension | Glaucoma

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied (VENERA)

Glaucoma, Neovascular

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (VEGA)

Glaucoma, Neovascular

Japan

3

Subscribe